Oncology test kit

serumurine

(in dev.) numares’ mission in oncology is to develop IVD tests that improve the care and management of patients with prostate, bladder and hepatic cellular cancer. This goal is achieved by developing and using metabolite constellations of cancer specific serum or urine biomarkers by NMR. By means of artificial intelligence and biostatistical modelling (machine learning), the metabolite constellations are evaluated in clinical studies for clinical correlation. The numares methodology is unique and powerful with a proven track record for identification of metabolite biomarkers, clinical validation and commercialization. In Oncology, our biomarker discovery pipeline will provide a new powerful tool in developing multi-parametric tests for cancer diagnosis, cancer progression monitoring and to evaluate therapeutic efficacy. Clinicians/laboratories: More information on the AXINON® IVD System Our oncology biomarker development pipeline and all future oncology tests will be available for the AXINON® IVD System which produces high-quality, standardized NMR spectra based on numares’ Magnetic Group Signaling (MGS®) technology. The combination of MGS® technology with the AXINON® IVD System allows for test-specific spectral analysis with highly-reproducible results. The test system is easy to use with one-step sample preparation with ready-to-use reagents requiring minimal operator interaction. The test system is fast and efficient with automation capabilities allowing short hands-on-time and high walk-away capability. To date, more than 2 million tests have been performed worldwide based on numares’ technology.